[go: up one dir, main page]

CY1110689T1 - Συνθεσεις οι οποιες περιλαμβανουν πολυπεπτιδια - Google Patents

Συνθεσεις οι οποιες περιλαμβανουν πολυπεπτιδια

Info

Publication number
CY1110689T1
CY1110689T1 CY20101100465T CY101100465T CY1110689T1 CY 1110689 T1 CY1110689 T1 CY 1110689T1 CY 20101100465 T CY20101100465 T CY 20101100465T CY 101100465 T CY101100465 T CY 101100465T CY 1110689 T1 CY1110689 T1 CY 1110689T1
Authority
CY
Cyprus
Prior art keywords
polypeptide
binding sites
compositions
antigen binding
polyptopes
Prior art date
Application number
CY20101100465T
Other languages
English (en)
Inventor
Robert Hofmeister
Nadja Prang
Andreas Wolf
Frank Hanakam
Thomas Urbig
Christian Itin
Patrick Baeuerle
Original Assignee
Micromet Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Micromet Ag filed Critical Micromet Ag
Publication of CY1110689T1 publication Critical patent/CY1110689T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται σε συνθέσεις οι οποίες περιλαμβάνουν πολυπεπτίδια, ειδικά πολυπεπτίδια ικανά για ειδική πρόσδεση σε προπροσδιορισμένα αντιγόνα μέσω επιτόπων στα εν λόγω αντιγόνα. Το πολυπεπτίδιο στην σύνθεση περιλαμβάνει τουλάχιστον δύο θέσεις πρόσδεσης αντιγόνου. Αυτές οι τουλάχιστον δύο θέσεις πρόσδεσης αντιγόνου εντοπίζονται σε μία μόνο πολυπεπτιδική αλυσίδα. Μία από τις εν λόγω τουλάχιστον δύο θέσεις πρόσδεσης αντιγόνου προσδένει ειδικά το ανθρώπινο CD3 αντιγόνο. Το πολυπεπτίδιο μπορεί να υπάρχει και σε μονομερή και σε πολυμερή μορφή. Η πολυμερής μορφή του πολυπεπτιδίου αποτελεί όχι περισσότερο από το 5% του συνολικού βάρους των συνδυασμένων μονομερών και πολυμερών μορφών του εν λόγω πολυπεπτιδίου.
CY20101100465T 2003-11-28 2010-05-27 Συνθεσεις οι οποιες περιλαμβανουν πολυπεπτιδια CY1110689T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03027511 2003-11-28
EP04803302A EP1691833B1 (en) 2003-11-28 2004-11-26 Compositions comprising polypeptides

Publications (1)

Publication Number Publication Date
CY1110689T1 true CY1110689T1 (el) 2015-06-10

Family

ID=34626385

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20101100465T CY1110689T1 (el) 2003-11-28 2010-05-27 Συνθεσεις οι οποιες περιλαμβανουν πολυπεπτιδια
CY2016010C CY2016010I1 (el) 2003-11-28 2016-05-05 Συνθεσεις οι οποιες περιλαμβανουν πολυπεπτιδια

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY2016010C CY2016010I1 (el) 2003-11-28 2016-05-05 Συνθεσεις οι οποιες περιλαμβανουν πολυπεπτιδια

Country Status (18)

Country Link
US (1) US10000574B2 (el)
EP (2) EP2186527A1 (el)
AT (1) ATE459374T1 (el)
AU (1) AU2004293182B2 (el)
BE (1) BE2016C023I2 (el)
CA (1) CA2544532C (el)
CY (2) CY1110689T1 (el)
DE (1) DE602004025840D1 (el)
DK (1) DK1691833T3 (el)
ES (1) ES2341252T3 (el)
FR (1) FR16C1000I2 (el)
HU (1) HUS1600019I1 (el)
LU (1) LU93067I2 (el)
NL (1) NL300807I2 (el)
PL (1) PL1691833T3 (el)
PT (1) PT1691833E (el)
SI (1) SI1691833T1 (el)
WO (1) WO2005052004A2 (el)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME01786B (me) 2006-08-14 2014-09-20 Xencor Inc Optimizovana antitela usmerena na cd19
PL2066349T3 (pl) 2006-09-08 2012-09-28 Medimmune Llc Humanizowane przeciwciała anty-CD19 i ich zastosowanie w leczeniu nowotworów, transplantacjach i leczeniu chorób autoimmunologicznych
JP5490714B2 (ja) * 2007-11-28 2014-05-14 メディミューン，エルエルシー タンパク質製剤
US8658765B2 (en) 2009-12-31 2014-02-25 Avidbiotics Corp. Non-natural MIC proteins
US8796420B2 (en) 2009-12-31 2014-08-05 Avidbiotics Corp. Non-natural MIC proteins
LT3018145T (lt) 2010-10-27 2018-05-10 Amgen Research (Munich) Gmbh Priemonės ir būdai dlbcl gydymui
EP3138581B1 (en) 2011-03-17 2019-01-02 The University of Birmingham Re-directed immunotherapy
JP2014518615A (ja) 2011-04-22 2014-08-07 エマージェント プロダクト デベロップメント シアトル， エルエルシー 前立腺特異的膜抗原結合タンパク質および関連組成物ならびに方法
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
AU2014364593A1 (en) 2013-12-17 2016-07-07 Genentech, Inc. Methods of treating cancer using PD-1 axis binding antagonists and an anti-CD20 antibody
RS59659B2 (sr) 2013-12-17 2023-08-31 Hoffmann La Roche Postupci lečenjа raka pomoću аntаgonistа koji vežu osovinu pd-1 i pomoću tаksаnа
KR20220025917A (ko) 2014-05-29 2022-03-03 마크로제닉스, 인크. 삼중-특이적 결합 분자 및 그것의 사용 방법
RU2705274C2 (ru) 2014-11-05 2019-11-06 Дженентек, Инк. Способы получения двуцепочечных белков в бактериях
EP3753948A1 (en) 2014-11-05 2020-12-23 Genentech, Inc. Methods of producing two chain proteins in bacteria
EP3253419A1 (en) 2015-02-02 2017-12-13 The University of Birmingham Targeting moiety peptide epitope complexes having a plurality of t-cell epitopes
AU2016271142A1 (en) 2015-05-29 2017-11-23 Genentech, Inc. PD-L1 promoter methylation in cancer
AU2016280070B2 (en) 2015-06-17 2022-09-15 Genentech, Inc. Methods of treating locally advanced or metastatic breast cancers using PD-1 axis binding antagonists and taxanes
JP7002446B2 (ja) 2015-09-21 2022-03-04 アプティーボ リサーチ アンド デベロップメント エルエルシー Ｃｄ３結合ポリペプチド
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
EP3377103B2 (en) 2015-11-19 2025-03-12 Revitope Limited Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells
CN108290954B (zh) 2015-12-09 2022-07-26 豪夫迈·罗氏有限公司 Ii型抗cd20抗体用于降低抗药物抗体形成
EP3178848A1 (en) 2015-12-09 2017-06-14 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
CN108368179B (zh) 2016-01-08 2022-08-23 豪夫迈·罗氏有限公司 使用pd-1轴结合拮抗剂和抗cea/抗cd3双特异性抗体治疗cea阳性癌症的方法
EP3252078A1 (en) 2016-06-02 2017-12-06 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
CN109963871A (zh) 2016-08-05 2019-07-02 豪夫迈·罗氏有限公司 具有激动活性的多价及多表位抗体以及使用方法
CN109476748B (zh) 2016-08-08 2023-05-23 豪夫迈·罗氏有限公司 用于癌症的治疗和诊断方法
CA3039430A1 (en) 2016-12-19 2018-06-28 F. Hoffmann-La Roche Ag Combination therapy with targeted 4-1bb (cd137) agonists
PL3559034T3 (pl) 2016-12-20 2021-04-19 F. Hoffmann-La Roche Ag Terapia skojarzona dwuswoistymi przeciwciałami anty-CD20/anty-CD3 i agonistami 4-1BB (CD137)
MX2019014274A (es) 2017-06-02 2020-01-23 Hoffmann La Roche Metodo de tratamiento.
MX2020004573A (es) 2017-11-01 2020-09-25 Hoffmann La Roche Terapia de combinacion con agonistas de ox40 dirigidos.
CA3092002A1 (en) 2018-03-13 2019-09-19 F. Hoffmann-La Roche Ag Therapeutic combination of 4-1 bb agonists with anti-cd20 antibodies
TWI841551B (zh) 2018-03-13 2024-05-11 瑞士商赫孚孟拉羅股份公司 使用靶向4-1bb (cd137)之促效劑的組合療法
CA3102562A1 (en) * 2018-06-07 2019-12-12 Cullinan Management, Inc. Multi-specific binding proteins and methods of use thereof
MX2021003213A (es) 2018-09-21 2021-05-12 Genentech Inc Metodos de diagnostico para cancer de mama triple negativo.
JP7620546B2 (ja) 2018-11-05 2025-01-23 ジェネンテック， インコーポレイテッド 原核宿主細胞における２鎖タンパク質の産生方法
EP3962948A1 (en) 2019-04-30 2022-03-09 Amgen Research (Munich) GmbH Means and methods of treating burkitt lymphoma or leukemia
KR20230031981A (ko) 2019-05-14 2023-03-07 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
WO2020236792A1 (en) 2019-05-21 2020-11-26 Novartis Ag Cd19 binding molecules and uses thereof
MX2022015872A (es) 2020-06-11 2023-05-16 Provention Bio Inc Metodos y composiciones para prevenir diabetes tipo 1.
IL299039A (en) 2020-06-16 2023-02-01 Genentech Inc Methods and preparations for the treatment of triple-negative breast cancer
KR102453073B1 (ko) 2020-08-14 2022-10-11 건국대학교 글로컬산학협력단 피키아 파스토리스를 이용한 이중특이적 항체의 제조방법 및 이에 따른 이중특이적 항체
US20240101673A1 (en) 2021-02-03 2024-03-28 Mozart Therapeutics, Inc. Binding agents and methods of using the same
JP2024518709A (ja) 2021-04-10 2024-05-02 プロファウンドバイオ ユーエス カンパニー Ｆｏｌｒ１結合剤、そのコンジュゲートおよびこれを使用する方法
WO2022226317A1 (en) 2021-04-23 2022-10-27 Profoundbio Us Co. Anti-cd70 antibodies, conjugates thereof and methods of using the same
TW202243689A (zh) 2021-04-30 2022-11-16 瑞士商赫孚孟拉羅股份公司 抗ｃｄ２０／抗ｃｄ３雙特異性抗體及抗ｃｄ７８ｂ抗體藥物結合物的組合治療之給藥
EP4083061A1 (en) * 2021-04-30 2022-11-02 Kilometro Rosso SPA Fusion proteins and use thereof in the treatment of membranous nephropathy
TW202244059A (zh) 2021-04-30 2022-11-16 瑞士商赫孚孟拉羅股份公司 用抗ｃｄ２０／抗ｃｄ３雙特異性抗體進行治療之給藥
TW202320857A (zh) 2021-07-06 2023-06-01 美商普方生物製藥美國公司 連接子、藥物連接子及其結合物及其使用方法
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors
IL314211A (en) 2022-03-23 2024-09-01 Genentech Inc Combined treatment of bispecific antibody and chemotherapy against CD20/ANTI-CD3
CN119013300A (zh) 2022-04-13 2024-11-22 豪夫迈·罗氏有限公司 抗cd20/抗cd3双特异性抗体的药物组合物和使用方法
WO2024030956A2 (en) 2022-08-03 2024-02-08 Mozart Therapeutics, Inc. Cd39-specific binding agents and methods of using the same
WO2024094741A1 (en) 2022-11-03 2024-05-10 F. Hoffmann-La Roche Ag Combination therapy with anti-cd19/anti-cd28 bispecific antibody
WO2024243423A1 (en) 2023-05-24 2024-11-28 Mozart Therapeutics, Inc. Cd8-specific binding proteins and methods of using the same
WO2024261013A1 (en) 2023-06-21 2024-12-26 F. Hoffmann-La Roche Ag Combination therapy with fap-targeted lymphotoxin beta receptor agonists

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
AU612370B2 (en) 1987-05-21 1991-07-11 Micromet Ag Targeted multifunctional proteins
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
ATE241011T1 (de) 1991-02-27 2003-06-15 Micromet Ag Serin-reiche peptidlinker
US5525491A (en) 1991-02-27 1996-06-11 Creative Biomolecules, Inc. Serine-rich peptide linkers
US5656730A (en) * 1995-04-07 1997-08-12 Enzon, Inc. Stabilized monomeric protein compositions
AU761587B2 (en) * 1998-04-21 2003-06-05 Amgen Research (Munich) Gmbh CD19xCD3 specific polypeptides and uses thereof
US20020142964A1 (en) * 2000-11-02 2002-10-03 Nissen Torben Lauesgaard Single-chain polypeptides
US20030138417A1 (en) * 2001-11-08 2003-07-24 Kaisheva Elizabet A. Stable liquid pharmaceutical formulation of IgG antibodies

Also Published As

Publication number Publication date
WO2005052004A2 (en) 2005-06-09
DE602004025840D1 (de) 2010-04-15
FR16C1000I1 (el) 2016-06-24
ATE459374T1 (de) 2010-03-15
PT1691833E (pt) 2010-06-08
WO2005052004A3 (en) 2006-03-09
CY2016010I2 (el) 2016-08-31
BE2016C023I2 (el) 2023-12-18
EP2186527A1 (en) 2010-05-19
HUS1600019I1 (hu) 2016-06-28
PL1691833T3 (pl) 2010-08-31
CA2544532A1 (en) 2005-06-09
US20070249529A1 (en) 2007-10-25
CY2016010I1 (el) 2016-08-31
LU93067I2 (fr) 2016-07-11
CA2544532C (en) 2015-06-16
AU2004293182A1 (en) 2005-06-09
NL300807I2 (el) 2016-10-13
US10000574B2 (en) 2018-06-19
EP1691833B1 (en) 2010-03-03
SI1691833T1 (sl) 2010-06-30
ES2341252T3 (es) 2010-06-17
DK1691833T3 (da) 2010-05-03
FR16C1000I2 (fr) 2017-02-03
AU2004293182B2 (en) 2010-02-18
EP1691833A2 (en) 2006-08-23

Similar Documents

Publication Publication Date Title
CY1110689T1 (el) Συνθεσεις οι οποιες περιλαμβανουν πολυπεπτιδια
ATE370967T1 (de) Polyspezifische bindemoleküle und deren verwendung
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
CY1119291T1 (el) Πολυσθενη αντισωματα και χρησεις για αυτα
CY1119650T1 (el) Anti-il-12 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
ATE533784T1 (de) Lösliche, einzelkettige proteine des t- zellrezeptors
CY1121162T1 (el) M-csf-ειδικο μονοκλωνικο αντισωμα και χρησεις αυτου
CY1113400T1 (el) Αλλαγη των συγγενειων συνδεσης me fcrn ή των ημιζωων ορου αντισωματων με μεταλλαξιγενεση
CY1105563T1 (el) Συνθεσεις ανοσοποιησης και μεθοδοι χρησης
CY1110877T1 (el) Αλλαγη των συγγενειων συνδεσης me fcrn ή των ημιζωων ορου αντισωματων με μεταλλαξιγενεση
HRP20000714B1 (en) NOVEL CD19xCD3 SPECIFIC POLYPEPTIDES AND USES THEREOF
CY1110579T1 (el) Η λειτουργια ενος υποδοχεα απτοσφαιρινης-αιμοσφαιρινης και οι χρησεις αυτου
CY1112993T1 (el) Παραγοντες ειδικης δεσμευσης της αγγειοποιητινης-2 και της αγγειοποιητινης-1
ATE469176T1 (de) Modifizierter anti-tnf antikörper
CY1111966T1 (el) Αντισωματα που δεσμευονται με κυτταροσυνδετο ca 125/0722ρ και μεθοδοι χρησεις αυτων
NO20060189L (no) Antistoffer mot interleukin-22 og anvendelse derav
ATE187494T1 (de) Multivalente einkettige antikörper
CY1108799T1 (el) Αντισωμα αντι- ccr5
DE69939820D1 (de) Internalisierende erbb2 antikörper
WO1997046589A3 (en) Humanized antibodies that bind to the same antigen as bound by antibody nr-lu-13, and their use in pretargeting methods
CY1106876T1 (el) Συσκευασια και μεθοδος ανιχνευσεως της πρωτεϊνης esm-1
CY1115295T1 (el) Συνθεση για την θεραπεια παθολογιας συνδεομενης με msrv/herv-w
CY1106200T1 (el) Αντισωματα εναντια σε κασπαση-8, παρασκευη και χρηση τους
ATE131069T1 (de) Composition comprising at least two different antibodies or fragments thereof.
WO2002076406A3 (en) Antibodies against autoantigens of primary biliary cirrhosis and methods of making and using them